| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Repligen Corporation has a current Overall Rating of D (Negative). | 7 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Repligen Corporation | 42 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: REPLIGEN CORP | 5 |
$25 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Repligen Corp | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | REPLIGEN CORP (RGEN=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | REPLIGEN CORP (RGEN=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Comprehensive Rating Report | 48 |
$99 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: REPLIGEN -- RGEN | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: CBRX , CPEX , CYAN , DRRX , DUSA , MAPP , MRNA , RGEN -- DRUGS | 3 |
$4 |
1.48% Nasdaq 0.00%
Research Reports
